"Arvind Vasudeva, Chief Executive Officer (Formulations), has resigned from the services of the company to pursue his professional interests with effect from the close of business hours on June 30, 2015," Aurobindo Pharma said in a filing to the BSE.
Recently, the drug firm had said that it intends to invest up to Rs 900 crore this fiscal on various activities including capacity expansion, clinical trials and product filings.
The company has presence in semi-synthetic penicillins and other key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins among others.